ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
64 038,56
1,83%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. UroGen Pharma Ltd (URGN)

  7. UroGen Pharma Ltd (URGN) Actualités

URGN UroGen Pharma Ltd

14,30
0,04 (0,28%)
04 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
UroGen Pharma Ltd URGN NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,04 0,28% 14,30 01:22:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
14,50 14,14 14,70 14,30 14,26
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
04/5/202421:20BWUroGen Announces Results from ATLAS Showing Robust UGN-102..
04/5/202417:50BWNew Real-World Study on Retrograde Instillation of JELMYTO®..
03/5/202414:00BWUroGen Pharma to Report 2024 First Quarter Financial Results..
17/4/202418:02BWUroGen Announces New Data Presentations at the American..
15/4/202414:00BWUroGen Announces FDA Acceptance of Investigational New Drug..
03/4/202414:00BWUroGen Pharma Files Patent Infringement Action Against Teva..
14/3/202413:00BWUroGen Pharma Delivers Double Digit JELMYTO® Growth and..
08/3/202414:00BWUroGen Pharma Announces Inducement Grants Under Nasdaq..
04/3/202414:00BWUroGen Pharma to Report Fourth Quarter and Full-Year 2023..
04/3/202413:00EDGAR2Form 8-K - Current report
01/3/202413:00EDGAR2Form 8-K - Current report
26/2/202414:00BWUroGen Pharma to Present at TD Cowen 44th Annual Health Care..
12/2/202423:47EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
07/2/202422:15EDGAR2Form 8-K - Current report
03/2/202401:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/2/202401:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/2/202401:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/2/202401:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202416:13EDGAR2Form 144 - Report of proposed sale of securities
01/2/202415:53EDGAR2Form 144 - Report of proposed sale of securities
01/2/202414:00BWUroGen Pharma to Participate at Upcoming Investor..
24/1/202414:00BWUroGen Initiates Submission of a Rolling NDA to the FDA for..
17/1/202422:16EDGAR2Form 8-K - Current report
17/1/202414:00BWUroGen Secures Exclusive License from medac GmbH to Develop..
11/1/202414:00BWUroGen Pharma to Participate in the B. Riley Healthcare..
02/1/202414:04EDGAR2Form 8-K - Current report
08/12/202322:00BWUroGen Pharma Announces Inducement Grants Under Nasdaq..
14/11/202322:20EDGAR2Form S-8 - Securities to be offered to employees in employee..
14/11/202314:00BWUroGen Pharma Reports Third Quarter 2023 Financial Results
13/11/202314:00BWUroGen will Present Scientific Advances in Bladder Cancer at..
07/11/202314:00BWUroGen Pharma to Report Third Quarter 2023 Financial Results..
03/10/202314:00BWFollowing Pre-NDA Meeting with the FDA, UroGen Announces..
11/9/202322:15EDGAR2Form 8-K - Current report
11/9/202313:00GLOBEEledon Pharmaceuticals Appoints Industry Veteran James..
08/9/202322:16EDGAR2Form S-3 - Registration statement under Securities Act of..
08/9/202321:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/9/202321:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/9/202321:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/9/202321:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/9/202321:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/9/202321:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/9/202321:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/9/202314:00BWUroGen Pharma Announces Inducement Grants Under Nasdaq..
05/9/202322:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/8/202314:00BWUroGen Pharma to Present at Upcoming Investor Conferences
10/8/202314:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202314:01EDGAR2Form 8-K - Current report
10/8/202314:00BWUroGen Pharma Reports Record JELMYTO Quarterly Sales and..
08/8/202314:00BWThe Journal of Urology Publishes Peer-Reviewed Article..
04/8/202314:56EDGAR2Form SC 13D - General statement of acquisition of beneficial..

Dernières Valeurs Consultées

NASDAQ
URGN
UroGen Pharma
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés